UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 319

Sortiert nach

WS21.5 Real life evaluation of the introduction of Freestyle Libre continuous glucose system versus capillary blood glucose monitoring in patients with cystic fibrosis related diabetes

Journal of cystic fibrosis, 2017-06, Vol.16, p.S35-S35

2017

Link zum Volltext

Verfügbarkeit prüfen

WS08.2 Exploring the potential impact of gastro-oesophageal reflux on CF lung disease

Journal of cystic fibrosis, 2017-06, Vol.16, p.S14-S14

2017

Link zum Volltext

Verfügbarkeit prüfen

293 Reflux, acid suppression therapy and nutritional outcomes in CF

Journal of cystic fibrosis, 2017-06, Vol.16, p.S137-S137

2017

Link zum Volltext

Verfügbarkeit prüfen

182 Impact of ivacaftor on glycaemic health in patients carrying the G551D mutation

Journal of cystic fibrosis, 2015-06, Vol.14, p.S104-S104

2015

Link zum Volltext

Verfügbarkeit prüfen

ePS06.10 Antibiotic desensitisation: a single centre review of 2015

Journal of cystic fibrosis, 2016-06, Vol.15, p.S50-S50

2016

Link zum Volltext

Verfügbarkeit prüfen

93 The use of MALDI-TOF MS for the identification of non-fermenting Gram-negative bacilli isolated from cystic fibrosis patients

Journal of cystic fibrosis, 2016-06, Vol.15, p.S74-S75

2016

Link zum Volltext

Verfügbarkeit prüfen

WS17.3 Errors in documentation of genotype results in a large adult CF centre

Journal of cystic fibrosis, 2015-06, Vol.14, p.S31-S31

2015

Link zum Volltext

Verfügbarkeit prüfen

321 Changes in lung function and airway microbiology following ivacaftor therapy in an adult G551D homozygote

Journal of cystic fibrosis, 2015-06, Vol.14, p.S140-S140

2015

Link zum Volltext

Verfügbarkeit prüfen

EPS5.05 Elexacaftor/tezacaftor/ivacaftor (ETI) - nutritional benefits are greatest for those in greatest need

Journal of cystic fibrosis, 2023-06, Vol.22, p.S50-S50

2023

Link zum Volltext

Verfügbarkeit prüfen

Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes

The New England journal of medicine, 2021-08, Vol.385 (9), p.815-825

2021

Link zum Volltext

Verfügbarkeit prüfen

Modelling of marine debris pathways into UK waters: Example of non-native crustaceans transported across the Atlantic Ocean on floating marine debris

Marine pollution bulletin, 2023-01, Vol.186, p.114388-114388, Article 114388

2023

Link zum Volltext

Verfügbarkeit prüfen

WS12-1 Longitudinal effects of ivacaftor therapy in adults with the G551D mutation - a 5-year study

Journal of cystic fibrosis, 2019-06, Vol.18, p.S21-S22

2019

Link zum Volltext

Verfügbarkeit prüfen

54 UK and Ireland review of ivacaftor in severe CF: Impact on hospitalisations and antibiotic use

Journal of cystic fibrosis, 2013-06, Vol.12, p.S62-S62

2013

Link zum Volltext

Verfügbarkeit prüfen

WS7.6 UK and Ireland review of ivacaftor in severe CF: Impact on lung function and weight

Journal of cystic fibrosis, 2013-06, Vol.12, p.S15-S15

2013

Link zum Volltext

Verfügbarkeit prüfen

P147 Longitudinal effects of ivacaftor on Aspergillus fumigatus serology and culture in eligible adults with cystic fibrosis

Journal of cystic fibrosis, 2020-06, Vol.19, p.S97-S97

2020

Link zum Volltext

Verfügbarkeit prüfen

P224 Evolution of dry powder inhaled colistimethate sodium (Colobreathe®) in a large adult cystic fibrosis centre

Journal of cystic fibrosis, 2022-06, Vol.21, p.S129

2022

Link zum Volltext

Verfügbarkeit prüfen

P038 ELX/TEZ/IVA discontinuation is more common in an older population

Journal of cystic fibrosis, 2022-06, Vol.21, p.S71

2022

Link zum Volltext

Verfügbarkeit prüfen

WS04.05 What is the scope for colorectal cancer screening in cystic fibrosis? Ten years of experience at a UK cystic fibrosis centre

Journal of cystic fibrosis, 2022-06, Vol.21, p.S8-S9

2022

Link zum Volltext

Verfügbarkeit prüfen

P101 Microbiological surveillance in cystic fibrosis – an emerging multifactorial challenge

Journal of cystic fibrosis, 2022-06, Vol.21, p.S91-S92

2022

Link zum Volltext

Verfügbarkeit prüfen

P158 What is the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on clinical response of cystic fibrosis patients aged ≥ 40 years and their comorbidities?

Journal of cystic fibrosis, 2022-06, Vol.21, p.S109

2022

Link zum Volltext

Verfügbarkeit prüfen

Polypharmacy in older cancer patients in Ireland

Journal of geriatric oncology, 2013-10, Vol.4, p.S78-S78

2013

Link zum Volltext

Verfügbarkeit prüfen

IPD2.06 Ivacaftor therapy in patients with severe baseline lung disease carrying a residual function mutation

Journal of cystic fibrosis, 2018-06, Vol.17, p.S55-S55

2018

Link zum Volltext

Verfügbarkeit prüfen

P222 Home delivery influences medicines possession ratio in adult cystic fibrosis

Journal of cystic fibrosis, 2018-06, Vol.17, p.S122-S122

2018

Link zum Volltext

Verfügbarkeit prüfen

P172 Different spirometry equipment produces clinically important differences in lung function measurements in adults with cystic fibrosis

Journal of cystic fibrosis, 2020-06, Vol.19, p.S104-S105

2020

Link zum Volltext

Verfügbarkeit prüfen

P036 Relationship between phenotype and genotype in an older cystic fibrosis cohort

Journal of cystic fibrosis, 2020-06, Vol.19, p.S65-S65

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 319

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(258)
Mit Volltextzugriff
(283)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(189)
Life Sciences & Biomedicine
(113)
Technology
(53)
Physical Sciences
(50)
Engineering
(43)
Humans
(43)
Biological And Medical Sciences
(41)
Agriculture
(36)
Engineering, Electrical & Electronic
(36)
Exact Sciences And Technology
(32)
Female
(24)
Fundamental And Applied Biological Sciences. Psychology
(23)
Applied Sciences
(22)
Northern America
(22)
Social Sciences
(21)
U.S
(21)
Physics
(20)
Animals
(19)
Economics
(19)
Medical Sciences
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

WS21.5 Real life evaluation of the introduction of Freestyle Libre continuous glucose system versus capillary blood glucose monitoring in patients with cystic fibrosis related diabetes

WS08.2 Exploring the potential impact of gastro-oesophageal reflux on CF lung disease

293 Reflux, acid suppression therapy and nutritional outcomes in CF

182 Impact of ivacaftor on glycaemic health in patients carrying the G551D mutation

ePS06.10 Antibiotic desensitisation: a single centre review of 2015

93 The use of MALDI-TOF MS for the identification of non-fermenting Gram-negative bacilli isolated from cystic fibrosis patients

WS17.3 Errors in documentation of genotype results in a large adult CF centre

321 Changes in lung function and airway microbiology following ivacaftor therapy in an adult G551D homozygote

EPS5.05 Elexacaftor/tezacaftor/ivacaftor (ETI) - nutritional benefits are greatest for those in greatest need

Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes

Modelling of marine debris pathways into UK waters: Example of non-native crustaceans transported across the Atlantic Ocean on floating marine debris

WS12-1 Longitudinal effects of ivacaftor therapy in adults with the G551D mutation - a 5-year study

54 UK and Ireland review of ivacaftor in severe CF: Impact on hospitalisations and antibiotic use

WS7.6 UK and Ireland review of ivacaftor in severe CF: Impact on lung function and weight

P147 Longitudinal effects of ivacaftor on Aspergillus fumigatus serology and culture in eligible adults with cystic fibrosis

P224 Evolution of dry powder inhaled colistimethate sodium (Colobreathe®) in a large adult cystic fibrosis centre

P038 ELX/TEZ/IVA discontinuation is more common in an older population

WS04.05 What is the scope for colorectal cancer screening in cystic fibrosis? Ten years of experience at a UK cystic fibrosis centre

P101 Microbiological surveillance in cystic fibrosis – an emerging multifactorial challenge

P158 What is the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on clinical response of cystic fibrosis patients aged ≥ 40 years and their comorbidities?

Polypharmacy in older cancer patients in Ireland

IPD2.06 Ivacaftor therapy in patients with severe baseline lung disease carrying a residual function mutation

P222 Home delivery influences medicines possession ratio in adult cystic fibrosis

P172 Different spirometry equipment produces clinically important differences in lung function measurements in adults with cystic fibrosis

P036 Relationship between phenotype and genotype in an older cystic fibrosis cohort

Suchergebnisse filtern